Allosteric adenosine receptor modulators
AssigneeKing Pharmaceutical Research & Development, Inc.
InventorPier Giovanni Baraldi
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds of formula (IA): the preparation thereof, pharmaceutical formulations thereof, and their use in medicine as allosteric adenosine receptor modulators for uses including protection against hypoxia and ischemia induced injury and treatment of adenosine-sensitive cardiac arrhythmias.
Claims11
A method for providing cardioprotection, neuroprotection, pain management, reduction of free fatty acids, triglycerides, or glucose levels, adjunct therapy in diabetes, treatment of GI disorders, treatment of glaucoma;
- treatment of sleep disorders;
- treatment of cardiac disarrythmias (peroxysmal supraventricular tachycardia, treatment of congestive heart failure or treatment of inflammation comprising administering to a patient in need of treatment thereof an effective amount to treat the disorder of a compound of formula IA:
- wherein
- R2 is H, C(═O)R8;
- R8 is H, alkyl, substituted alkyl, aralkyl, substituted aralkyl, aryl, or substituted aryl;
- R3 and R4 are independently H, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, halogen, hydroxy, alkylsulfonyloxy, arylsulfonyloxy, substituted arylsulfonyloxy, alkoxy, alkylthio, or arylthio;
- or if R3 and R4 are both alkoxy or alkylthio, may form a 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl, 1,3-dithiolan-2-yl, or 1,3-dithian-2-yl group;
- or together R3 and R4 may form a carbonyl oxygen;
- R5, R6, and R7 are independently H, alkyl, substituted alkyl, aryl, substituted aryl, halogen, hydroxy, nitro, amino, substituted amino, disubstituted amino, alkoxy, aryloxy, alkylthio, arylthio, sulfonamido, or substituted sulfonamido;
- or together R5 and R6 or R6 and R7 may be CH═CH—CH═CH, such that they form a fused aromatic ring;
- A and B are independently O, S, or N—R8;
- except either A or B, but not both A and B, may independently represent a carbon—carbon single bond;
- m and n are independently 0, 1 or 2;
- when A or B represents a carbon-carbon single bond then m plus n equals 2;
- when neither A nor B represent a carbon-carbon single bond then m plus n equals 1;
- and
- X is CH═CH, CH═N, N═CH, O, S, or N—R8.
A method for providing cardioprotection, neuroprotection, pain management, reduction of free fatty acids, triglycerides, or glucose levels, adjunct therapy in diabetes, treatment of GI disorders, treatment of glaucoma;
- treatment of sleep disorders;
- treatment of cardiac disarrythmias, peroxysmal supraventricular tachycardia, treatment of congestive heart failure or treatment of inflammation comprising administering to a patient in need of treatment thereof an effective amount to treat the disorder of a compound selected from thc group consisting of:
- (2-Amino-4,7-dihydro-5H-thieno[2,3-thiopyran-3-yl)-phenyl-methanone;
- (2-Amino-4,7-dihydro-5H-thieno[2,3-thiopyran-3-yl)-(4-chlorophenyl)-methanone;
- (2-Amino-6-benzyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-3-yl)-naphthalen-1-yl-methanone;
- (2-Amino-6-benzyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-3-yl)-furan-2-yl-methanone;
- (2-Amino-6-benzyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-3-yl)-benzofuran-2-yl-methanone;
- (2-Amino-6-benzyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-3-yl)-pyridin-2-yl-methanone;
- (2-Amino-6-benzyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-3-yl)-naphthalen-2-yl-methanone;
- (2-Amino-6-benzyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-3-yl)-thiophen-2-yl-methanone;
- (2-Amino-6-benzyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-3-yl)-(5-bromothiophen-2-yl)-methanone;
- (2-Amino-6-benzyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-3-yl)-(5-chlorothiophen-2-yl)-methanone;
- [2-Amino-6-benzyl-4,5,6,7-tetrahydrothieno(2,3-c)pyridin-3-yl]-thiophen-3-yl-methanone;
- [2-Amino-6-(4-methoxyphenyl)-4H-1,5,7-trithia-inden-3-yl]-napthalen-1-yl-methanone;
- [2-Amino-6-(4-methoxyphenyl)-4H-1,5,7-trithia-inden-3-yl]-(4-chlorophenyl)-methanone;
- [2-Amino-6-(4-methoxyphenyl)-4H-1,5,7-trithia-inden-3-yl]-thiophen-2-yl-methanone;
- (2-Amino-6-benzyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-3-yl)-(9H-fluoren-2-yl)-methanone;
- [2-Amino-6-(4-chlorobenzyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-3-yl]-naphthalen-2-yl-methanone;
- 2-Amino-6-(4-fluorobenzyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-3-yl]-naphthalen-2-yl-methanone;
- [2-Amino-6-(2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-3-yl]-naphthalen-2-yl-methanone;
- [2-Amino-6-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-3-yl]-naphthalen-2-yl-methanone;
- and
- [2-Amino-6-(3,4,5-trimethoxybenzyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-3-yl]-naphthalen-2-yl-methanone.
A method for determining whether a compound is active at moderating adenosine receptors in a mammal, comprising performing competitive binding studies with the compound to be analyzed and a compound selected from a group consisting of compounds of formula IA:
- wherein R2 is H, C(═O)R8;
- R8 is H, alkyl, substituted alkyl, aralkyl, substituted aralkyl, aryl, or substituted aryl;
- R3 and R4 are independently H, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, halogen, hydroxy, alkylsulfonyloxy, arylsulfonyloxy, substituted arylsulfonyloxy, alkoxy, alkylthio, or arylthio;
- or if R3 and R4 are both alkoxy or alkylthio, may form a 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl, 1,3-dithiolan-2-yl, or 1,3-dithian-2-yl group;
- or together R3 and R4 may form a carbonyl oxygen;
- R5, R6, and R7 are independently H, alkyl, substituted alkyl, aryl, substituted aryl, halogen, hydroxy, nitro, amino, substituted amino, disubstituted amino, alkoxy, aryloxy, alkylthio, arylthio, sulfonamido, or substituted sulfonamido;
- or together R5 and R6 or R6 and R7 may be CH═CH—CH═CH, such that they form a fused aromatic ring;
- A and B are independently O, S, or N—R8;
- except either A or B, but not both A and B, may independently represent a carbon—carbon single bond;
- m and n are independently 0, 1 or 2;
- when A or B represents a carbon—carbon single bond then m plus n equals 2;
- when neither A nor B represent a carbon—carbon single bond then m plus n equals 1;
- and
- X is CH═CH, CH═N, N═CH, O, S, or N—R8.
Dependencies are inferred from the claim text.